tenatoprazole
Small moleculeexperimental
Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003. The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00282555)
Timeline
Indications
Mechanism of action
- Cytochrome P450 2C19INHIBITOR
CYP2C19 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2n1- Mol. weight
- 346.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaTenatoprazole ↗
- ChEMBLCHEMBL1475252 ↗
Also known as
- s-tenatoprazole
- s-tenatoprazole
- tenatoprazole
- tenatoprazole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00284908 | Phase 1 | Sep 1, 2006 | Healthcare Discoveries Inc., Steba Biotech S.A. |
| NCT00282555 | Phase 2 | Feb 1, 2006 | Steba Biotech S.A., University of Alberta |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Steba Biotech S.A. | For profit | 2 | 2 | 2 | 2006 |
| Healthcare Discoveries Inc. | For profit | 1 | 0 | 1 | 2006 |
| University of Alberta | Academic/Hospital | 1 | 0 | 1 | 2006 |
3 organizations
Page 1 / 1